Rationale for the study — the presence of limitations in the use of traditional markers of diabetes mellitus (DM) and pre-diabetes causes the search for alternative markers for diagnosis and prognosis in patients with coronary heart disease (CHD). Objective. To determine the diagnostic value of 1.5-anhydroglucitol (1,5-AH) for carbohydrate metabolism disorders in patients with CHD with indications to selected percutaneous coronary intervention (PCI). Material and methods. A prospective study was conducted during the period from November 2016 to November 2017 in patients admitted to the selected PCI in Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases. In all patients, concentrations of the markers of carbohydrate metabolism disorders: fasting glucose, glycated hemoglobin (HbA1c), fructosamine and 1.5-AH were measured. The latter was by enzyme immunoassay. The results of the research were processed by Statistica Windows 6.0. and MedCal. Results. The level of 1.5-AH was significantly different in patients with DM and without carbohydrate metabolism disorders. The level of 1.5-AH was lower in patients with an unacceptable target HbA1c level. Correlation analysis revealed a weak inverse relationship between 1.5-AH and HbA1c (r= –0.17), fasting glucose (r= –0.22) and postprandial hyperglycaemia (r= –0.23). According to the results of the ROC analysis, statistically significant results of the sensitivity and specificity of 1.5-AH were obtained only in the diabetes group (AUC 0.609, 95% CI: 0.511—0.707). Conclusion. According to the results of the study, 1.5-AH was correlated with other markers of carbohydrate metabolism disorders (HbA1c, fasting glucose and postprandial hyperglycaemia). The level of 1.5-AH <15.5 μg/ml was a reliable diagnostic marker of diabetes mellitus in patients with CHD and indications to PCI, which allows it to be considered as an additional diagnostic tool.